Patent Clock Ticks for LITFULO After FDA Review Period
Published Date: 5/12/2025
Notice
Summary
The FDA has officially set the review period for LITFULO, a human drug product, so its patent can be extended. This helps the drug maker get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this means important timing updates and potential market exclusivity changes.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Patent Extension Eligibility Set
The FDA has determined the regulatory review period for the drug LITFULO so its patent can be extended. This lets the patent holder seek extra time to protect the invention after the drug approval process.
Timing and Exclusivity Updates for Developers
The notice provides timing updates related to LITFULO's regulatory review period and says there could be changes to the drug's market exclusivity. If you work on drug patents or development, this alerts you to important timing and exclusivity effects for LITFULO.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in